Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease. (ExercisPompe)
Primary Purpose
Pompe Disease, Muscle Weakness
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Resistance Exercise Training
Sponsored by
About this trial
This is an interventional treatment trial for Pompe Disease focused on measuring exercise, Pompe disease, Pompe
Eligibility Criteria
Inclusion Criteria:
- Able to fully consent to the protocol.
- Physically able to perform resistance exercises for 12 weeks.
- Patients with a confirmed diagnosis of Pompe disease.
- Age 16 years to 75 years.
- Currently receiving ERT.
- Patient on ERT for at least 1year.
Exclusion Criteria:
- Patients with no confirmed diagnosis of Pompe disease, either by GAA enzyme deficiency from any tissue and/or molecular testing revealing two GAA gene mutations
- Unable to walk or cycle
- Unable to consent to the study/ procedures
- Women who are pregnant or breastfeeding
- Heart disease
- Patients with any metal inside their body such as metallic clips used for vascular repairs and/or implanted devices such as cardiac pacemakers which would prevent them from doing the MRI.
Sites / Locations
- UCI ICTS (Institute for Clinical and Translational Science)
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Resistance Exercise Training
Arm Description
Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
Outcomes
Primary Outcome Measures
Isometric muscle strength change from week 8 through week 32
Secondary Outcome Measures
6 Minute Walk Test change from week 8 through week 32
Maximum Inspiratory Pressures percent change from week 8 through week 32
MRC score change from week 8 through week 32
Muscle volume and texture change from week 8 through week 32 using MR Imaging
Glycogen content change in quadriceps muscle from week 8 through week 32
GAA enzyme activity change from week 8 through week 32
HEX4 change from week 8 through week 32
Other spirometry parameters change from week 8 through week 32
Full Information
NCT ID
NCT02654886
First Posted
December 10, 2015
Last Updated
September 24, 2019
Sponsor
University of California, Irvine
1. Study Identification
Unique Protocol Identification Number
NCT02654886
Brief Title
Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
Acronym
ExercisPompe
Official Title
Safety and Effectiveness of Resistance Exercise Training in Patients With Late Onset Pompe Disease- A Pilot Study
Study Type
Interventional
2. Study Status
Record Verification Date
September 2019
Overall Recruitment Status
Completed
Study Start Date
October 2015 (Actual)
Primary Completion Date
August 6, 2018 (Actual)
Study Completion Date
September 24, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Irvine
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this research study is to determine if exercise will help improve muscle strength, endurance, and quality of life in individuals with Pompe disease. This is a research study to further define the outcome of patients with Pompe disease treated with a combined diet and exercise therapy.
Detailed Description
Eligibility: Subjects that are age 16 years or older, have been diagnosed with Pompe disease by genetic testing, and are showing symptoms such as muscle weakness
Time Commitment:
The study will last for 8 months. This study consists of a baseline visit of and return visits at week 9, week 16, week 24, and week 32. At the week 9 visit the subject will be given an individualized exercise plan which will be carried out over the next 24 weeks. The subject will be asked to return for three more visits at week16, week 24 and week 32. The 24 week training period will involve 3 workouts a week approximately 15-30 minutes each. It will also involve a breathing exercise that the subject can do at home twice daily for 10-15 minutes per session. The study visits will include the exercise plan, physical exam, blood draw and questionnaires.
Anticipated Benefits:
The possible benefits include a delay in progression of muscle weakness. The knowledge gained from this study will help researchers understand the effect of exercise on the disease. This may eventually lead to new forms of prevention of symptom onset in the future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pompe Disease, Muscle Weakness
Keywords
exercise, Pompe disease, Pompe
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Resistance Exercise Training
Arm Type
Experimental
Arm Description
Participants will be given a regimen of resistance training after a 2 month observation period. Participants will be trained for 6 months (total= 72 training sessions). Two muscle groups (limbs) would be included in the resistance-training program. Participants will also be initiated with Respiratory muscle strength training using pressure-threshold respiratory trainers.
Intervention Type
Other
Intervention Name(s)
Resistance Exercise Training
Intervention Description
Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months
Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months
Primary Outcome Measure Information:
Title
Isometric muscle strength change from week 8 through week 32
Time Frame
Eight months
Secondary Outcome Measure Information:
Title
6 Minute Walk Test change from week 8 through week 32
Time Frame
Eight months
Title
Maximum Inspiratory Pressures percent change from week 8 through week 32
Time Frame
Eight months
Title
MRC score change from week 8 through week 32
Time Frame
Eight months
Title
Muscle volume and texture change from week 8 through week 32 using MR Imaging
Time Frame
Eight months
Title
Glycogen content change in quadriceps muscle from week 8 through week 32
Time Frame
Eight months
Title
GAA enzyme activity change from week 8 through week 32
Time Frame
Eight months
Title
HEX4 change from week 8 through week 32
Time Frame
Eight months
Title
Other spirometry parameters change from week 8 through week 32
Time Frame
Eight months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
16 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Able to fully consent to the protocol.
Physically able to perform resistance exercises for 12 weeks.
Patients with a confirmed diagnosis of Pompe disease.
Age 16 years to 75 years.
Currently receiving ERT.
Patient on ERT for at least 1year.
Exclusion Criteria:
Patients with no confirmed diagnosis of Pompe disease, either by GAA enzyme deficiency from any tissue and/or molecular testing revealing two GAA gene mutations
Unable to walk or cycle
Unable to consent to the study/ procedures
Women who are pregnant or breastfeeding
Heart disease
Patients with any metal inside their body such as metallic clips used for vascular repairs and/or implanted devices such as cardiac pacemakers which would prevent them from doing the MRI.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Virginia Kimonis, MD MRCP
Organizational Affiliation
University of California, Irvine
Official's Role
Principal Investigator
Facility Information:
Facility Name
UCI ICTS (Institute for Clinical and Translational Science)
City
Irvine
State/Province
California
ZIP/Postal Code
92697
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
Yes
IPD Sharing Plan Description
Individual participant data will be made available to partcipants after data is published in a peer reviewed journal.
Citations:
PubMed Identifier
20838899
Citation
Bembi B, Pisa FE, Confalonieri M, Ciana G, Fiumara A, Parini R, Rigoldi M, Moglia A, Costa A, Carlucci A, Danesino C, Pittis MG, Dardis A, Ravaglia S. Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis. 2010 Dec;33(6):727-35. doi: 10.1007/s10545-010-9201-8. Epub 2010 Sep 14.
Results Reference
background
PubMed Identifier
9266214
Citation
Bodamer OA, Leonard JV, Halliday D. Dietary treatment in late-onset acid maltase deficiency. Eur J Pediatr. 1997 Aug;156 Suppl 1:S39-42. doi: 10.1007/pl00014270.
Results Reference
background
PubMed Identifier
19019308
Citation
Schoser B, Hill V, Raben N. Therapeutic approaches in glycogen storage disease type II/Pompe Disease. Neurotherapeutics. 2008 Oct;5(4):569-78. doi: 10.1016/j.nurt.2008.08.009.
Results Reference
background
PubMed Identifier
6401355
Citation
Slonim AE, Coleman RA, McElligot MA, Najjar J, Hirschhorn K, Labadie GU, Mrak R, Evans OB, Shipp E, Presson R. Improvement of muscle function in acid maltase deficiency by high-protein therapy. Neurology. 1983 Jan;33(1):34-8. doi: 10.1212/wnl.33.1.34.
Results Reference
background
PubMed Identifier
17022069
Citation
Slonim AE, Bulone L, Goldberg T, Minikes J, Slonim E, Galanko J, Martiniuk F. Modification of the natural history of adult-onset acid maltase deficiency by nutrition and exercise therapy. Muscle Nerve. 2007 Jan;35(1):70-7. doi: 10.1002/mus.20665.
Results Reference
background
PubMed Identifier
18776212
Citation
Sveen ML, Jeppesen TD, Hauerslev S, Kober L, Krag TO, Vissing J. Endurance training improves fitness and strength in patients with Becker muscular dystrophy. Brain. 2008 Nov;131(Pt 11):2824-31. doi: 10.1093/brain/awn189. Epub 2008 Sep 6.
Results Reference
background
PubMed Identifier
21640624
Citation
Terzis G, Dimopoulos F, Papadimas GK, Papadopoulos C, Spengos K, Fatouros I, Kavouras SA, Manta P. Effect of aerobic and resistance exercise training on late-onset Pompe disease patients receiving enzyme replacement therapy. Mol Genet Metab. 2011 Nov;104(3):279-83. doi: 10.1016/j.ymgme.2011.05.013. Epub 2011 May 19.
Results Reference
background
PubMed Identifier
15048888
Citation
Winkel LP, Van den Hout JM, Kamphoven JH, Disseldorp JA, Remmerswaal M, Arts WF, Loonen MC, Vulto AG, Van Doorn PA, De Jong G, Hop W, Smit GP, Shapira SK, Boer MA, van Diggelen OP, Reuser AJ, Van der Ploeg AT. Enzyme replacement therapy in late-onset Pompe's disease: a three-year follow-up. Ann Neurol. 2004 Apr;55(4):495-502. doi: 10.1002/ana.20019.
Results Reference
background
PubMed Identifier
26381077
Citation
Jones HN, Crisp KD, Robey RR, Case LE, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining. Mol Genet Metab. 2016 Feb;117(2):120-8. doi: 10.1016/j.ymgme.2015.09.003. Epub 2015 Sep 8.
Results Reference
background
PubMed Identifier
26187632
Citation
van den Berg LE, Favejee MM, Wens SC, Kruijshaar ME, Praet SF, Reuser AJ, Bussmann JB, van Doorn PA, van der Ploeg AT. Safety and efficacy of exercise training in adults with Pompe disease: evalution of endurance, muscle strength and core stability before and after a 12 week training program. Orphanet J Rare Dis. 2015 Jul 19;10:87. doi: 10.1186/s13023-015-0303-0.
Results Reference
background
Learn more about this trial
Safety and Effectiveness of Resistance Exercise Training in Patients With Pompe Disease.
We'll reach out to this number within 24 hrs